|
| 36375115 | Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600-Mutant Low-Grade Glioma. | J Clin Oncol | 2023 |
| 34435684 | Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. | Journal of Clinical Pharmacology | 2022 |
| 35395680 | Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). | Neuro Oncol | 2022 |
| 36307212 | Discovery and functional characterization of the oncogenicity and targetability of a novel <i>NOTCH1-ROS1</i> gene fusion in pediatric angiosarcoma. | Cold Spring Harb Mol Case Stud | 2022 |
| 36276356 | High prevalence of obesity among women in urban Haiti: Findings from a population-based cohort. | Frontiers in Public Health | 2022 |
| 35796027 | Exploring young Australians' understanding of sustainable and healthy diets: a qualitative study. | Public Health Nutrition | 2022 |
| 35733515 | Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. | Neurooncol Adv | 2022 |
| 35363510 | Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 35353553 | Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. | J Clin Oncol | 2022 |
| 36190525 | A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. | Clin Cancer Res | 2022 |
| 34347089 | Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. | Neuro Oncol | 2022 |
| 35278038 | Neuroblastoma and cutaneous angiosarcoma in a child with PTEN hamartoma tumor syndrome. | Pediatr Blood Cancer | 2022 |
| 35290915 | ACCELERATE - Five years accelerating cancer drug development for children and adolescents. | Eur J Cancer | 2022 |
| 34536944 | Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. | Eur J Cancer | 2021 |
| 33677616 | A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. | Cancer Chemotherapy and Pharmacology | 2021 |
| 33568345 | Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). | Clin Cancer Res | 2021 |
| 33881209 | A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). | Pediatric Blood and Cancer | 2021 |
| 34036219 | NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. | JCO Precis Oncol | 2021 |
| 33601323 | Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. | Eur J Cancer | 2021 |
| 33438318 | A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). | Pediatr Blood Cancer | 2021 |
| 34023919 | Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. | Cancer Chemother Pharmacol | 2021 |
| 33405268 | Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. | Laryngoscope | 2021 |
| 34898668 | Pharmacokinetics of the disialoganglioside, G, a circulating tumor biomarker for neuroblastoma, in nonhuman primates. | Journal of Circulating Biomarkers | 2021 |
| 34383370 | Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. | Pediatric Blood and Cancer | 2021 |
| 32571790 | Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. | Clin Cancer Res | 2020 |
| 31857431 | Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). | Clin Cancer Res | 2020 |
| 32421361 | How to address challenges and opportunities in pediatric cancer drug development? | Expert Opinion on Drug Discovery | 2020 |
| 32192573 | Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 |
| 31838007 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. | Lancet Oncol | 2020 |
| 31724813 | Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). | Pediatric Blood and Cancer | 2020 |
| 31612589 | The ganglioside G as a circulating tumor biomarker for neuroblastoma. | Pediatric Blood and Cancer | 2020 |
| 31812554 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 |
| 32992153 | Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2020 |
| 33095287 | Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). | Cancer Chemother Pharmacol | 2020 |
| 32914879 | ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. | Cancer | 2020 |
| 30777875 | A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). | Clin Cancer Res | 2019 |
| 31286189 | Population pharmacokinetics of trabectedin in adolescent patients with cancer. | Cancer Chemotherapy and Pharmacology | 2019 |
| 29693796 | A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. | Pediatric Blood and Cancer | 2018 |
| 30394521 | A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). | Cancer | 2018 |
| 29874142 | New Agents, Emerging Late Effects, and the Development of Precision Survivorship. | Journal of Clinical Oncology | 2018 |
| 30093449 | Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. | Clin Cancer Res | 2018 |
| 30368044 | A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, G, in human plasma or serum. | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences | 2018 |
| 29187393 | Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. | Clin Cancer Res | 2018 |
| 29719113 | A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). | Pediatric Blood and Cancer | 2018 |
| 29445029 | Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. | Oncologist | 2018 |
| 29176356 | Evolving paradigms for new agent development in pediatric oncology. | Current Opinion in Pediatrics | 2018 |
| 29292843 | Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). | Pediatric Blood and Cancer | 2018 |
| 28295182 | A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). | British Journal of Haematology | 2017 |
| 28509433 | Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. | Pediatric Blood and Cancer | 2017 |
| 28449393 | A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). | Pediatric Blood and Cancer | 2017 |